Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Pharmaron, a fully integrated contract research organization offering R&D services for the life science industry, has announced the acquisition of Xceleron Inc. Xceleron is a Maryland, US-based globally leading Accelerator Mass Spectrometry (AMS) ...
read more
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new validation service laboratory yesterday at its site in Shanghai Zhangjiang Hi-Tech Park. The opening event was attended by business ...
read more
Thursday, January 12, 2017
ChemDiv, Inc., a global research organization, announced achieving several key milestones in collaboration with Abbott's branded generics pharmaceutical business. The collaboration, begun in 2012 and expanded in 2015, is aimed at development and ...
read more
Wednesday, January 11, 2017
endpoint, an interactive response technology (IRT®) solutions company, has been selected as the sole IRT provider for Ferring Pharmaceuticals AS, a biopharmaceutical company based in Denmark.
read more
Wednesday, January 11, 2017
Mayne Pharma has announced the launch of Fabior® (tazarotene) Foam, 0.1% and Sorilux® (calcipotriene) Foam, 0.005% in the United States by Mayne Pharma’s Specialty Brands division.
read more
Wednesday, January 11, 2017
SGS has announced the forthcoming availability of a new strain of influenza virus for use as a challenge agent in clinical trials. The synthetic virus may be used to test the efficacy of both novel influenza drugs and vaccines in healthy volunteers.
read more
Wednesday, January 11, 2017
Parallel6™, a provider of mClinical technologies for improving patient enrollment, engagement, and management of clinical trials worldwide, has joined SAFE-BioPharma Association. SAFE-BioPharma manages the global digital identity management and ...
read more
Wednesday, January 11, 2017
Catalent Pharma Solutions has announced that it is to evaluate Jupiter Orphan Therapeutics, Inc.’s (JOT) novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology. Under the agreement, Catalent will ...
read more
Wednesday, January 11, 2017
Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck,, through a subsidiary, to add a new study of Lilly's LARTRUVO™ (olaratumab) with KEYTRUDA®(pembrolizumab) in patients with previously treated ...
read more
Tuesday, January 10, 2017
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis on silicon, announced that it is now shipping genes up to 3,200 base pairs (3.2 kilobase or kB) in length to Ginkgo Bioworks under their ...
read more
Tuesday, January 10, 2017
Drug discovery services and products provider Icagen, Inc. has announced an agreement with Japan-based drug discovery sales specialist On Target Co., Ltd. granting On Target Company, Ltd. rights to broker Icagen's products and services in this ...
read more
Orchard Therapeutics, a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases has announced an alliance with PharmaCell B.V., a Contract ...
read more
Metabolon, Inc. has entered into an agreement with InnVentis Ltd. to apply metabolomics in individuals with chronic inflammatory diseases, such as rheumatoid arthritis. InnVentis aims to bring together multi-omics technologies with clinical data and ...
read more
Curis has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015. As previously reported, the extension of exclusivity is associated with a payment of $7....
read more
EyeGate Pharmaceuticals has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. under the Company’s License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, ...
read more